Comment from Oracle America

Summary: Oracle Health and Life Sciences supports the FDA's proposed pilot program to explore AI-enabled technologies for improving the efficiency, quality, and safety of early-phase clinical trials. They recommend a risk-proportionate governance framework, a broad therapeutic scope, and the inclusion of metrics that prioritize operational outcomes, data integrity, and lifecycle monitoring.